Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Marta Mosca, Kenneth Kalunian et al.|The Lancet|2023Cited by 164